demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
potential COVID-19 treatments
adjuvant therapies
anticoagulant X-COVID-19
anticoagulant, curative dose COALIZAO ACTION ATTACC, ACTIV-4a, and REMAP-CAP ... REMAP-CAP, ACTIV-4a, ATTACC ... COVID-PACT
anticoagulation, intermediate prophylactic dose INSPIRATION
heparin at therapeutic dose RAPID ... ATTACC ... ACTIV-4a ... REMAP-CAP Anticoagulation
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
anti GM-CSF
mavrilimumab MASH-COVID ...
clarithromycine Rashad ...
colchicine COLCOVID Lopes MIF Salehzadeh GRECCO-19 RECOVERY ... Horby COL-COVID ... COLCHIVID
Colchicine plus rosuvastatin COLSTAT Gaitan-Duarte ...
non-steroidal anti-inflammatory drugs Guzman-Esquivel
Indomethacin Ravichandran
stem cells Lanzoni Carmenate ... Shu Shi
vilobelimab (IFX-1) PANAMO
corticosteroids GLUCOCOVID
dexamethasone RECOVERY dexamethasone DEXA-COVID19 CODEX ... Jamaati Rashad Naik
Dexamethasone 12mg COVID STEROID 2
Hydrocortisone CAPE-COVID REMAP-CAP, fixed 7-day course REMAP-CAP, shock-dependent course Munch ...
methylprednisolone Tang X Metcovid Ranjbar Steroids-SARI Edalatifard Farahani
Immunostimulants drugs
convalescent plasma treatment ConCOVID ... ConPlas-19 COP-COVID-19 CONTAIN COVID-19 PC/COVID-19 NCT04397757 PLACO-COVID CONCOR-1 CPC-SARS NCT04442191 DAWN-Plasma NCT04385199 COPLA-II trial NCT04403477 ... ASCOT RECOVERY ... CONFIDENT PERUCONPLASMA Bennett-Guerrero Salman Kirenga LACCPT Co-CLARITY NCT04528368 Holm K CCAP-2 Baldeon Menichetti LIFESAVER PLACID Libster CP-COVID-19 ILBS-COVID-02 ... Li Rasheed O’Donnell PlasmAr CAPSID AlQahtani REMAP-CAP ... RECOVER PICP19 ... Pouladzadeh Sekine ... Ray
Early convalescent plasma. Balcells
immunoglobulin therapy Sakoulas Parikh Tabarsi Gharebaghi Raman
interferon
IFN beta-1a SOLIDARITY ... Davoudi-Monfared Darazam ... Kalil ...
high-dose IFN beta-1a Darazam
IFN beta-1b Rahmani Darazam ...
IFN gamma Esquivel-Moynelo
inhaled interferon
IFN alpha
pegylated interferon-α2b Pandit Shashi Bhushan
recombinant super-compound interferon rSIFN-co Li
SNG001 inhaled interferon beta Synairgen SG016 SPRINTER
interferon / TFF2 Fu
peginterferon Jagannathan
PNB001 Lattmann
neutralizing antibody ITAC
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) ACTIV-3 ...
bamlanivimab monotherapy ACTIV-3/TICO LY-CoV555
casirivimab/imdevimab (Ronapreve) RECOVERY ... Somersan-Karakaya ...
cilgavimab and tixagevimab (Evusheld) ACTIV-3/TICO ...
equine polyclonal antibodies INM005 Lopardo
sotrovimab (Xevudy; VIR-7831) ACTIV-3/ TICO ...
Immunosuppressants drugs
abatacept ACTIV-1 abatacept
adalimumab Fakharian
anakinra SAVE-MORE CORIMUNO-ANA-1
anti-interleukin-6
Levilimab V.Lomakin ...
sarilumab CORIMUNO-SARI-1 ... sarilumab Sanofi phase 3 US sarilumab Sanofi phase 3 outside US REMAP-CAP sarilumab
sarilumab high dose (400mg) sarilumab phase 2 high dose Lescure ...
sarilumab low dose (200mg) sarimulab phase 2 low dose Lescure ...
tocilizumab Dongsheng Wang RCT-TCZ-COVID-19 EMPACTA RECOVERY Soin AS ... Rutgers NCT04412772 ... Declercq J ... NCT04577534 ... EU-CTR2020-001375-32 ... EU-CTR2020-001748-24 ... NCT04479358 ... NCT04434717 ... TOCOVID BACC Bay Tocilizumab Trial MARIPOSA COVACTA ... CORIMUNO-TOCI-1 ... REMAP-CAP ... Veiga Rashad Talaschian Hamed CORIMUNO-TOCI-ICU ... NCT04377750 ... Rosas ... Sarhan Sarhan
canakinumab Sheng ... CAN-COVID
cenicriviroc ACTIV-1 cenicriviroc
infliximab ACTIV-1 infliximab
itolizumab Kumar
janus kinase (JAK) inhibitor
baricitinib COV-BARRIER ACTT-2 ... RECOVERY COV-BARRIER ...
ruxolitinib Cao DEVENT
TD-0903
TD-0903 10mg Singh ...
TD-0903 1mg Singh ...
TD-0903 3mg Singh ...
tofacitinib STOP-COVID ... Murugesan
lenzilumab LIVE-AIR ...
tacrolimus TACROVID
thalidomide Amra
Kinase inhibitors
acalabrutinib CALAVI CALAVI US
imatinib Covid-19 HUF Aman
leflunomide Wang et al. Wang
statins
Atorvastatin INSPIRATION-S
antiandrogenic
progesterone Ghandehari
proxalutamide Cadegiani
antiviral and associated therapy
azithromycin Sekhavati RECOVERY ... COALITION I Covid-19 Brazil ... Rashad A ... COALITION II Covid-19 Brazil ...
azvudine Ren
baloxavir marboxil Lou Y
bromhexine Ansarin Tolouian Li T
chloroquine and derivatives
chloroquine Huang Chen, ChiCTR2000030054 - Chloroquine NCT04342650
hydroxychloroquine Tang HAHPS ORCHID Duke University hydroxychloroquine/azithromycine RECOVERY SOLIDARITY ... Chen NO COVID-19 ... Abd-Elsalam CCAP-1 Duke university HCQ ARCHAIC -hydroxychloroquine PROTECT B TEACH OAHU-COVID19 HYCOVID IRCT20200428047228N1 // U07 Gonzalez ... PROTECT A ChiCTR2000030054-HCQ ... IRCT20150808023559N20 IRCT20150808023559N20 NOR-Solidarity ... HC-nCoV ... Zhaowei Chen Coalition Covid-19 Brazil I ... NCT04333654 FACCT Trial Dubee Kamran REMAP-CAP-HCQ HYDRA ... Sarhan Sarhan
darunavir cobicistat Jun C
Emtricitabine/tenofovir plus colchicine plus rosuvastatin Gaitan-Duarte ...
Ensitrelvir (XOCOVA) Mukae - Phase 2a
favipiravir IRCT20200428047228N1 // U07 Udwadia AVIFAVIR Lou ... Chang Chen et al. NCT04310228-FAVI ... jRCTs041190120 IRCT20150808023559N20 IRCT20150808023559N20 Dabbous HM Holubar M IRCT20151227025726N14 // U07 FACCT Trial Udwadia AVIFAVIR Shenoy S NCT04542694 Ruzhentsova T Solaymani-Dodaran Shinkai
favipiravir plus interferon Khamis
hydroxychloroquine plus macrolides Duke university HCQ-AZI
azithromycin plus hydroxychloroquine ProPAC-COVID Coalition Covid-19 Brazil I ...
ivermectin Gonzalez ... Shahbaznejad Ahmed Chachar Chaccour Bukhari Kirti Babalola RIVET-COV ... Abd-Elsalam Krolewiecki I-TECH ... Mayer Okumuş Galan Galan
ivermectin plus doxycycline Hashim A NCT04523831 ...
lopinavir/ritonavir RECOVERY SOLIDARITY ... Nojomi Ader ... ELACOI ... Cao REMAP-CAP ...
Lopinavir/ritonavir plus hydroxychloroquine REMAP-CAP ...
lopinavir/ritonavir plus interferon ß-1a Ader ...
lopinavir/ritonavir, ribavirin and interferon beta-1b Hung et al.
niclosamide Abdulamir
nirmatrelvir / ritonavir (Paxlovid) EPIC-SR
nitazoxanide Rocco Silva Fontanesi
opaganib Winthrop
remdesivir NIH NIAID ACTT-1 DisCoVeRy ... SOLIDARITY ... Mahajan Norwegian NOR study ... Andreas ... GS-US-540-5774, 10 days GS-US-540-5774, 5 days GS-US-540-5773 ... CAP-China ...
sofosbuvir Sali Alavi-moghaddam
sofosbuvir and daclatasvir Sadeghi Yakoot Mobarak S ... Mobarak ...
sofosbuvir and ledipasvir Elgohary Nourian A
tenofovir/emtricitabine Gaitan-Duarte ...
umifenovir (arbidol) UAIIC Nojomi ELACOI ... Yethindra ELACOI ...
zinc Patel
Drugs for acid related disorders
H2 blockers
famotidine Samimagham
miscellaneous
alpha lipoic acid Ming Zhong
Aspirin RECOVERY ...
aviptadil COVID-AIV ACTIV-3 Critical Care
camostat mesilate Gunst JD
Cannabidiol Crippa ...
honey Silveira
povidone-iodine Mohamed
pyridostigmine Fragoso-Saavedra ...
sabizabulin VERU-111
Oral antidiabetic drugs
dapagliflozin DARE-19
DPP-4 inhibitor Guardado-Mendoza Abuhasira
Renin-angiotensin-system-acting agents
angiotensin receptor blockers (ARBs) Duarte Nouri-Vaskeh
losartan University of Minnesota
discontinuation of ACEI/ARB REPLACE Najmeddin Lopes ...
Vitamins
vitamin C Zhang Jamali Moghadam Siahkali Kumari
Vitamin D Entrenas ... Murai Rastogi COVID-VIT-D
hight dose vitamin D COVIT-TRIAL

60 studies excluded by filtering options 1

5092 Yang, 2020 1133not a RCThigh risk of bias
5228 Bean, 2020 1193not a RCThigh risk of bias
5295 Zhang, 2020 1133not a RCThigh risk of bias
5331 Li, 2020 1134not a RCThigh risk of bias
5332 Meng, 2020 1134not a RCThigh risk of bias
5345 Yan et al., 2020 1204not a RCThigh risk of bias
5346 Mancia, 2020 1203not a RCThigh risk of bias
5347 Mehra, 2020 2124excludednot a RCThigh risk of bias
5348 Reynolds (COVID positive patient), 2020 1133not a RCThigh risk of bias
5349 Reynolds (prophylaxis), 2020 1133not a RCThigh risk of bias
5370 Khera (outpatients), 2020 1133not a RCThigh risk of bias
5372 Khera (inpatients), 2020 1133not a RCThigh risk of bias
5399 Northwell Consortium (Richardson), 2020 0990selection pending
5440 Morales, 2020 1130not a RCTrisk of bias not avaialble
5604 Schneeweiss, 0 0130selection pending
5605 Vila-Corcole, 0 0130selection pending
5619 Pan, 2020 0130selection pending
5797 Rossi, 0 0130selection pending
5903 Anzola, 2020 0100selection pending
6660 Bae, 2021 0120selection pending
6729 Shah, 2021 1133not a RCThigh risk of bias
6788 Waissengrin, 2021 0130selection pending
6790 Pawlowski, 2021 1130not a RCTrisk of bias not avaialble
6894 Andrejko, 2021 1200not a RCTrisk of bias not avaialble
6927 Rossman, 2021 0130selection pending
6931 Yair, 2921 1320not a RCTrisk of bias not avaialble
6934 Boyarsky, 2021 1320not a RCTrisk of bias not avaialble
6949 Pawlowski, 2021 1130not a RCTrisk of bias not avaialble
6981 Public Health England (Harris), 2021 1133not a RCThigh risk of bias
7025 Haberman, 2021 0130selection pending
7070 PHE variants (Technical briefing 12 22 may 2021), 2021 2202excludednot a RCT
7325 Skowronski, 2021 0130selection pending
7419 Scotland delta (Sheikh), 2021 1203not a RCThigh risk of bias
7420 PHE (Stowe), 2021 2133excludednot a RCThigh risk of bias
7950 Harris, 2021 1133not a RCThigh risk of bias
8143 Butt, 2021 1202not a RCT
8147 Canada (Nasreen), 2021 1202not a RCT
8149 PHE Technical briefing 16 (11/18 June 2021), 2021 2133excludednot a RCThigh risk of bias
8150 Ramasamy, 2021 0320selection pending
8164 Public Health England, May 16, 2021 (Bernal), 2021 1202not a RCT
8255 REACT-SCOT, 2021 1200not a RCTrisk of bias not avaialble
8272 Martinez-Baz, 2021 1130not a RCTrisk of bias not avaialble
8274 REACT-1 round 13 final report (Elliott, Imperial College London), 2021 1133not a RCThigh risk of bias
8275 Musser, 2021 2130excludednot a RCTrisk of bias not avaialble
8294 CDC Mesa County, Colorado, 2021 1133not a RCThigh risk of bias
8313 Bahl (Fully vaccinated vs unvaccinated), 2021 0100selection pending
8350 Rosenberg, 2021 2130excludednot a RCTrisk of bias not avaialble
8359 Oxford (Pouwels), 2021 1132not a RCT
8360 HEROES-RECOVER (Fowlkes), 2021 1133not a RCThigh risk of bias
8513 Grannis, 2021 1203not a RCThigh risk of bias
8514 VA (Bajema), 2021 1203not a RCThigh risk of bias
8515 Scobie, 2021 2200excludednot a RCTrisk of bias not avaialble
9170 UKHSA report 33 (23 december 2021), 2021 2200excludednot a RCTrisk of bias not avaialble
9176 UKHSA 31 december 2021, 2021 2200excludednot a RCTrisk of bias not avaialble
9214 Southern California (Lewnard), 2022 2130excludednot a RCTrisk of bias not avaialble
9216 Sultan, 2022 0120selection pending
9267 Ostropolets, 2021 0120selection pending
9294 UKHSA (report W4- 27 January), 2022 2120excludednot a RCTrisk of bias not avaialble
9491 Li X, 2022 1120not a RCTrisk of bias not avaialble
9590 UKHSA report week 12 (24 March 2022), 2022 1120not a RCTrisk of bias not avaialble